"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...

By integrating NVIDIA’s digital twins, foundation models, and perception AI, Multiply Labs is pioneering a new era of robotic ...

Northwestern Medicine and Tempus AI, Inc. are collaborating to expand access to genomic testing for Northwestern Medicine ...

The bad news for Philadelphia is that these advantages are being squandered by leadership that can’t translate assets into ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Thanks to genetic science, gene editing, and techniques like cloning, it’s now possible to move DNA through time, studying ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

The firm expects its $1.25 billion cash runway to cover operating and capital expenses through 2029, including development plans for key assets.